Cipla vs Apollo Hospitals Enterprise Q2 FY26

Cipla delivered an all-time high quarterly revenue of INR 7,589 crore (+8% YoY) with a robust EBITDA margin of 25%, driven by broad-based growth across One India, US Generics, One Africa, and EMEU. The US business contributed $233 million in revenue, with Cipla becoming the #1 player in the albuterol MDI market (22% share). The India branded business grew 7% YoY, with chronic mix improving to 61.8%. Management revised FY26 EBITDA margin guidance down to 22.75%-24% (from 23.5%-24.5%) due to higher R&D spend and declining Revlimid contribution. Key growth drivers include the tirzepatide (Yurpeak) launch in India, upcoming respiratory and peptide launches in the US, and continued momentum in EMEU. Risk: Revlimid revenue is expected to become immaterial from Q3, creating a near-term revenue gap that new launches may not fully offset.

Guidance read

FY26 EBITDA margin guidance revised to 22.75%-24%: Full-year EBITDA margin guidance lowered from 23.5%-24.5% due to higher R&D spend and declining Revlimid contribution. Generic Revlimid contribution immaterial from Q3 FY26: Revlimid revenue expected to be very small in Q3 and decline further as patent expires in January. Launch of four major respiratory assets by CY26: Includes generic Advair in Q4 2026 and three peptide assets including liraglutide. US revenue directional target of $1B next year: Run-rate expected to reach $1B in US revenue during next fiscal year, subject to approval timelines.

Risk read

Key risks include Revlimid revenue cliff — Generic Revlimid contribution expected to become immaterial from Q3 FY26, creating a revenue gap that new launches may not fully offset in the near term.; Execution risk on US pipeline launches — Delays in FDA approvals for key respiratory and peptide assets could impact the $1B US revenue target.; India branded business growth slowdown — India branded business grew only 7% YoY, below the market, due to weak acute season and team restructuring.; Tirzepatide exclusivity and competition — Potential competition from semaglutide generics and uncertainty over exclusivity terms with Lilly could limit tirzepatide upside..

Promise ledger

Of 2 tracked promises, management 0 met, 0 close, 2 missed.

Apollo Hospitals delivered a solid Q2 FY26 with consolidated revenue of INR 6,304 crore (+13% YoY) and EBITDA of INR 941 crore (+15% YoY). Healthcare services revenue grew 9% to INR 3,169 crore, driven by a 14% increase in high-complexity CONGO specialties, offsetting a 6% decline in medical admissions due to seasonality and a 1% impact from reduced Bangladesh patients. Apollo HealthCo revenue rose 17% to INR 2,661 crore, with digital losses narrowing to INR 71 crore from INR 101 crore. Management guided for organic hospital growth to return to 13% and expects six new hospitals to commission over the next four quarters, with aggregate EBITDA losses of ~INR 150 crore in FY27. A key risk is the potential margin drag from new hospital ramp-up costs, which management aims to mitigate through a INR 120 crore cost-saving program.

Guidance read

Organic hospital growth to return to 13%: Management expects healthcare services organic growth to revert to 13% as Bangladesh patients return (60% already back in October) and new markets are explored. Six new hospitals to commission by Q1 FY27: Pune and Defence Colony in Q3, Sarjapur and Kolkata in Q4, Hyderabad and Gurugram in Q1 FY27. Aggregate EBITDA losses from these hospitals expected at ~INR 150 crore in FY27. Apollo 24/7 break-even by Q4 FY26: Digital platform on course to break even by end of fiscal year, with all three lines (pharmacy, diagnostics, consults) already CM1 positive. HealthCo margin target of 7% by Q4 FY27: Apollo HealthCo targeting INR 25,000 crore revenue run rate with 7% EBITDA margin by Q4 FY27, supported by KEIMED integration and digital break-even.

Risk read

Key risks include New hospital ramp-up costs may pressure margins — EBITDA losses from six new hospitals could be ~INR 150 crore in FY27, potentially dragging consolidated margins if ramp-up is slower than expected.; Insurance pricing reset may limit ARPP growth — Insurance contracts are reset every two years; with some contracts up for renewal, pricing may not keep pace with inflation, impacting revenue per patient.; CGHS rate hike still at 65% discount to private tariffs — Despite recent CGHS rate increases, government business remains significantly less profitable than insurance or cash, limiting margin expansion from that segment..

Promise ledger

Scorecard data is being built as historical quarters are processed.